Summary of Product Characteristics (SmPC) - Solivito N powder for concentrate for solution for infusion
1 NAME OF THE MEDICINAL PRODUCT
Solivito N Powder for Concentrate for Solution for Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Thiamine Mononitrate 3.1mg
Sodium Riboflavine Phosphate 4.9mg
Nicotinamide 40mg
Pyridoxine Hydrochloride 4.9mg
Sodium Pantothenate 16.5mg
Sodium Ascorbate 113mg
Biotin 60 micrograms 0.06 mg
Folic Acid 0.4 mg
Cyanocobalamin 5 micrograms 0.005mg
One vial of Solivito N contains the following quantities of water-soluble vitamins;
Vitamin B1 2.5mg
Vitamin B2 3.6mg
Nicotinamide 40mg
Vitamin B6 4mg
Pantothenic acid 15mg
Biotin 60 micrograms
Folic acid 0.4mg
Vitamin B12 5 micrograms
Vitamin C 100mg
Excipients with known effect: methyl parahydroxybenzoate (E218) 0.5mg per vial.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion.
Lyophilised sterile yellow powder.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Solivito N is intended for use as a supplement in intravenous nutrition, providing the daily requirements of water and soluble vitamins in adults and children.
4.2 Posology and method of administration
Posology
One vial of Solivito N should be infused over a minimum period of two to three hours in patients with normal renal function so as to minimise renal losses.
Recommended dosage for adults and children weighing 10 kg or more
For adult patients and children weighing 10 kg or more the recommended daily dosage is the contents of one vial.
Recommended dosage for infants and children weighing under 10 kg
Children weighing less than 10 kg should be given 1/10 of the contents of one vial per kg body weight per day.
Recommended dosage for the elderly
No adjustment of the adult dosage should be required.
Method of Administration
For intravenous infusion after dilution.
For instructions on dilution of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
For special precautions during pregnancy, see section 4.6.
Interference with clinical laboratory tests
Biotin may interfere with laboratory tests that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results, depending on the assay. The risk of interference is higher in children and patients with renal impairment and increases with higher doses. When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed (e.g. thyroid test results mimicking Graves’ disease in asymptomatic patients taking biotin or false negative troponin test results in patients with myocardial infarction taking biotin). Alternative tests not susceptible to biotin interference should be used, if available, in cases where interference is suspected.
The laboratory personnel should be consulted when ordering laboratory tests in patients taking biotin.
4.5 Interaction with other medicinal products and other forms of interaction
Pyridoxine (Vitamin B6) can reduce the effect of levodopa. Some of the optic neuropathies appear to respond to massive doses of hydroxocobalamin and have been claimed to be adversely affected by administration of cyanocobalamin. Folic acid may lower the serum concentration of phenytoin and obscure pernicious anaemia.
4.6 Fertility, pregnancy and lactation
Solivito N is a supplement in TPN regimens, providing water-soluble vitamins. No hazard is expected if used in pregnancy at the recommended dosage, covering the daily requirements of vitamins B1, B2, B6, B12 and C.
4.7 Effects on ability to drive and use machines
Solivito N has no influence on the ability to drive and use machines.
4.8 Undesirable effects
| MedDRA | Very | Common | Uncommon | Rare | Very | Not |
| system | common ≥ | ≥1/100 to | ≥1/1,000 to | ≥1/10,000 | rare | known |
| organ | 1/10 | <1/10 | <1/100 | to <1/1, | <1/10, | (cannot |
| class | 000 | 000 | be | |||
| estimated | ||||||
| from the | ||||||
| available | ||||||
| data) | ||||||
| Immune | Anaphylactic | |||||
| system | reaction, | |||||
| disorders |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the:
Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
4.9 Overdose
In general overdosage with Solivito N is unlikely. No clinically significant effects are envisaged if overdose should occur. However, treatment would be symptomatic.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic Group: Vitamins, ATC Code: B05XC
Solivito N is formulated to supply water-soluble vitamins as part of a total parenteral nutrition regimen.
5.2 Pharmacokinetic properties
Solivito N is a product without interest for pharmacokinetic studies.
5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber, which are additional to that already included in other sections of the Summary of Product Characteristics.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Glycine (Aminoacetic Acid)
Methyl- parahydroxy-benzoate
Disodium Edetate
Water for Injections
6.2 Incompatibilities
Solivito N must only be added to or mixed with other medicinal products for which compatibility has been documented. Please refer to section 6.6.
6.3 Shelf life
18 months
6.4 Special precautions for storage
Store below 25°C
Keep the container in the outer carton in order to protect from light.
6.5 Nature and contents of container
10ml Glass Vial (Ph.Eur – Type I) with a butyl rubber stopper and a flip-off cap each containing 484mg lyophilised powder.
Pack Size: 1 x 10 vials.
6.6 Special precautions for disposal and other handling
Compatibility and instructions for use
All additions should be made aseptically.
For adults and children weighing 10kg or more:
The contents of one vial of Solivito N are dissolved by the aseptic addition of 10ml of one of the following:
(i) Vitlipid N adult or for children under 11 years of age Vitlipid N infant.
(ii) Intralipid 10% or 20%.
(iii) Glucose intravenous infusion (5% - 60%).
(iv) Water for injections.
The reconstituted mixtures (i) and (ii) should be aseptically transferred to Intralipid 10% or 20% for infusion. The reconstituted mixtures (iii) and (iv) should be added to either glucose solution (5% - 60%) or Intralipid 10% or 20%. In this way the basal requirements of the water-soluble vitamins are provided.
Solivito N may be added to parenteral nutrition admixtures containing carbohydrates, lipids, amino acids, electrolytes and trace elements provided that compatibility and stability have been confirmed.
For infants and children under 10kg:
The contents of one vial are dissolved by the aseptic addition of 10 ml of one of the following:
(i) Vitlipid N infant.
(ii) Intralipid 10% or 20%.
(iii) Glucose Intravenous Infusion (5% - 60%).
(iv) Water for Injection
The basal requirements for water-soluble vitamins in children are provided by 1.0ml of this reconstituted mixture per kg bodyweight.
The reconstituted mixtures (i) and (ii) should be aseptically transferred to Intralipid 10% or 20% for infusion. The reconstituted mixtures (iii) and (iv) should be added to either glucose solution (5% - 60%) or to Intralipid 10% or 20%.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Fresenius Kabi Limited
Cestrian Court
Eastgate Way
Manor Park
Runcorn
Cheshire
WA7 1NT
UK
8 MARKETING AUTHORISATION NUMBER(S)
PL 08828/0116
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
10/03/2009
10 DATE OF REVISION OF THE TEXT
29/05/2019